Viesosios istaigos Vilniaus universiteto ligonines Santaros kliniku filialas Nacionalinis vezio centras — Clinical Trial Site

16 Registered trials

7 Currently recruiting

Organisation

Viesosios istaigos Vilniaus universiteto ligonines Santaros kliniku filialas Nacionalinis vezio centras

Location

Vilnius, Lithuania

Identifier

ORG-100053776

Address

Santariskiu G. 1, Vilniaus M. Sav., 08406, Lithuania

Departments

.
Center of Medical Oncology
Chemoterapijos skyrius su dienos stacionaru
Chemotherapy Day Hospital of the Medical Oncology Center and Clinical Research Department
Chemotherapy Day Inpatient Unit
Chemotherapy department
Clinical Trial department
Department of Oncology
Department of Thoracic Surgery and Oncology
Medical Oncology
Medical oncology department
N/A
Thoracic surgery and oncology department
Urology

Clinical trials at this site (16)

Search interface

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R… Pending

2024-519818-31-01 Endometrial Cancer Advanced, Recurrent, Metastatic, or 5
A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting

2023-504957-11-00 Metastatic castration resistant prostate cancer 5 2026-03-24
A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting

2024-518777-34-00 B7-H4-Selected Advanced/Metastatic Endometrial Cancer. 5 2026-02-11
A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting

2023-510323-30-00 First-line treatment of recurrent or metastatic PD-L1+ 5 2025-01-24
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting

2023-504923-20-00 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer 5 2024-04-04
LSTA1 for subjects with newly diagnosed Glioblastoma Multiforme when added to standard of care (temozolomide) versus temozolomide Recruiting

2023-506813-23-00 Glioblastoma Multiforme 4 2023-12-18
Phase 1 Study of MK-1084 in KRAS mutant advanced solid tumors Recruiting

2022-501563-40-00 Solid tumor cancer and lung cancer 1 2021-12-16
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended

2024-519773-19-00 Gastroesophageal Junction Adenocarcinoma 5 2025-07-31
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Pa… Ended

2024-511212-24-00 Advanced solid tumors 9 2024-10-07
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer Ended

2024-511038-11-00 advanced prostate cancer 4 2024-09-24
Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended

2023-503501-11-00 Metastatic Non-small Cell Lung Cancer 5 2023-02-09
Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended

2023-503517-30-00 Extensive-stage small-cell lung cancer 5 2022-04-01
A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended

2022-502100-70-00 Participants with Microsatellite Instability-High (MSI- 10 2021-06-23
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended

2023-504959-27-00 Participants with Limited Stage-Small Cell Lung Cancer, 5 2020-12-09